Recent developments and future strategies for immunotherapy of insect venom allergy

Current Opinion in Allergy and Clinical Immunology

Volumn 3, Issue 4, 2003, Pages 299-303

  Müller, Ulrich R ^a  

^a Medical Department   (Switzerland)

Author keywords

Antihistamines; DNA vaccination; Peptide immunotherapy; Recombinant venom allergens

Indexed keywords

ANTIHISTAMINIC AGENT; BEE VENOM; BINDING PROTEIN; COMPLEMENTARY DNA; DNA VACCINE; EPITOPE; FEXOFENADINE; HISTAMINE RECEPTOR; IMMUNOGLOBULIN E; INSECT VENOM; PHOSPHOLIPASE A2; TERFENADINE;

ALLERGENICITY; ALLERGIC REACTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GENETIC ENGINEERING; HUMAN; HYMENOPTERA; IMMUNOMODULATION; IMMUNOTHERAPY; INSECT ALLERGY; POINT MUTATION; PREMEDICATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMIC DISEASE; T LYMPHOCYTE; TREATMENT PLANNING; VACCINATION;

ARTHROPOD VENOMS; DESENSITIZATION, IMMUNOLOGIC; DNA, RECOMBINANT; EPITOPES, T-LYMPHOCYTE; FORECASTING; HISTAMINE H1 ANTAGONISTS; HUMANS; HYPERSENSITIVITY, IMMEDIATE; INSECT BITES AND STINGS; PREMEDICATION; VACCINES, DNA;

EID: 17744410662     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200308000-00011     Document Type: Review

References (35)

1. Müller U, Mosbech H. Immunotherapy with Hymenoptera venoms: EAACI position paper. Allergy 1993; 48 (Suppl 14):37-46.
2. Rueff F, Przybilla B, Müller U, Mosbech H. The sting challenge test in Hymenoptera venom allergy. Allergy 1996; 51:216-225.
3. Müller U, Helbling A, Berchtold E. Immunotherapy with honey bee and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992; 89:529-535.
4. Oude Elberink J, de Monchy J, Van der Heide S, et al. Venom immunotherapy improves health related quality of life in patients with yellow jacket venom allergy. J Allergy Clin Immunol 2002; 110:174-182. In this large controlled randomized study the authors demonstrate, on the basis of a validated questionnaire, that venom immunotherapy significantly improves health-related quality of life in patients with Vespula venom allergy.
5. Ludolph-Hauser D, Rueff F, Fries C, et al. Constitutively raised serum concentration of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 2001; 357:361-362.
6. Fricker M, Helbling A, Schwartz L, Müller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in 10 patients. J Allergy Clin Immunol 1997; 27:915-920.
7. Berchtold E, Maibach R, Müller U. Reduction of side effects from rush immunotherapy with honey bee venom by pretreatment with terfenadine. Clin Exp Allergy 1992; 22:59-65.
8. Brockow K, Kiehn M, Riethmüller C, et al. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1997; 100:458-463.
9. Herman D, Melac M. Effect of pretreatment with cetirizine on side effects from rush-immunotherapy with honey bee venom. Allergy 1996; 51 (Suppl 31):68.
10. Reimers AR, Hari Y, Müller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 2000; 55:484-488.
11. Akdis CA, Blaser K. Immunologic mechanisms of allergen-specific immunotherapy. Adv Exp Med Biol 2001; 495:247-259.
12. Jutel M, Watanabe T, Klunker S, et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001; 413: 420-425.
13. Müller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001; 197:81-86.
14. Jutel M, Watanabe T, Akdis M, et al. Immune regulation by histamine. Curr Opin Immunol 2002; 14:735-740. This is an elegant analysis of the immune regulatory potential of histamine based on its interference with histamine receptors on T cells and antigen presenting cells.
15. Müller U. Recombinant Hymenoptera venom allergens. Allergy 2002; 57:570-576. A thorough update of honeybee, vespid and ant venom allergens which have been expressed in recombinant form, including diagnostic and therapeutic perspectives.
16. King TP, Spangfort MD. Structure and biology of stinging insect venom allergens. Int Arch Allergy Immunol 2000; 123:99-106.
17. Dudler T, Chen W, Wang S, et al. High-level expression in E. coli and rapid purification of enzymatically active honey bee venom phospholipase A2. Biochim Biophys Acta 1992; 1165:201-210.
18. Müller UR, Dudler T, Schneider T, et al. Type I skin reactivity to native and recombinant phospholipase A2 from honeybee venom is similar. J Allergy Clin Immunol 1995; 96:395-402.
19. Förster E, Dudler T, Gmachl M, et al. Natural and recombinant enzymatically active or inactive bee venom phospholipase A2 has the same potency to release histamine from basophils in patients with Hymenoptera allergy. J Allergy Clin Immunol 1995; 95:1229-1235.
20. 2. Clin Exp Allergy 1997; 27:915-920.
21. Soldatova L, Crameri R, Gmachl M, et al. Superior biologic activity of the recombinant bee venom allergen hyaluronidase expressed in baculovirus-infected insect cells as compared with Escherichia coli. J Allergy Clin Immunol 1998; 101:691-698.
22. Valenta R, Kraft D. From allergen structure to new forms of allergen specific immunotherapy. Curr Opin Immunol 2002; 4:718-727. An elegant discussion of the potential of recombinant technology in immunotherapy of allergic diseases.
23. Soldatova LN, Tinh N, Markovic-Housley Z, et al. Biological activity of glycosylation and active site mutants of honey bee venom hyaluronidase. J Allergy Clin Immunol 2001; 107:222.
24. Carballido J, Carballido M, Kägi M, et al. T cell epitope specificity in human allergic and non allergic subjects to bee venom phospholipase A2. J Immunol 1993; 150:3582-3591.
25. 2 epitopes using short or long overlapping synthetic peptides: interest for specific immunotherapy. Clin Exp Allergy 1997; 27:1016-1026.
26. Dhillon M, Roberts C, Nunn T, Kuo M. Mapping T cell epitopes on phospholipase A2: the major bee venom allergen. J Allergy Clin Immunol 1992; 90:42-51.
27. Müller U, Akdis C, Fricker M, et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998; 101:747-754.
28. Norman P, Ohman J, Long A, et al. Treatment of cat allergy with T cell reactive peptides. Am J Respir Crit Care Med 1996; 154:1623-1628.
29. Akdis CA, Akdis M, Blesken T, et al. Epitope specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996; 98:1676-1683.
30. Von Garnier C, Astori M, Kettner A, et al. Allergen derived long peptide immunotherapy down-regulates specific IgE response and protects. Eur J Immunol 2000; 30:1638-1645.
31. Astori M, von Garnier C, Kettner A, et al. Inducing tolerance by intranasal administration of long peptides in naive and primed CBA/J mice. J Immunol 2000; 165:3497-3505.
32. Spertini F, Fellrath J, Kettner A, et al. Allergen peptide immunotherapy: results of a safety and immunogenicity trial with phospholipase A2-derived long peptides in bee venom hypersensitive patients. J Allergy Clin Immunol 2000; 104:S378-S379.
33. Spiegelberg H, Raz E. DNA-based approaches to the treatment of allergies. Curr Opin Mol Ther 2002; 4:64-71. Excellent review of the perspectives of this fascinating new technology.
34. Jilek S, Barbey C, Spertini F, Corthesy B. Antigen independent suppression of the allergic immune response to bee venom phospholipase A2 by DNA vaccination in CBA/J mice. Immunology 2001; 166:3612-3621.
35. Karamanloo F, Schmid-Grendelmeier P, Kussebi F, et al. Gene recombination of major bee venom allergen fragments as a novel vaccine for allergen specific immunotherapy. Allergo J 2002; 11:379.